Table 1.
Baseline Characteristics
| Pioglitazone (n = 6) | Placebo (n = 7) | p-value | |
|---|---|---|---|
| Age (years) | 52 (5) | 53 (6) | 0.72 |
| Gender (n): male/ female | 5/1 | 4/3 | 0.30 |
| Hispanic or Latino ethnicity | 0 | 1 | 0.25 |
| Race (n): black/white | 6/0 | 6/1 | 0.25 |
| BMI (kg/m2) | 29.2 (3.1) | 30.5 (5.0) | 0.52 |
| Systolic blood pressure (mm Hg) | 130 (14) | 129 (19) | 1.0 |
| Diastolic blood pressure (mm Hg) | 77 (8) | 77 (9) | 0.89 |
| Total CD4 count (cells/ml) | 485 (108) | 667 (221) | 0.18 |
| HIV viral load below detection limit (n) | 6 (0 viremic) | 5 (2 viremic) | 0.10 |
| Hepatitis C virus (IU/ml) | 11.5 × 106 (15.7 × 106) | 21.7 × 106 (27.9 × 106) | 0.52 |
| Hepatitis C genotype 1a/1b (n) | 3/3 | 4/3 | 0.79 |
| ALT (IU/liter) | 58 (20) | 53 (27) | 0.57 |
| AST (IU/liter) | 48 (26) | 43 (17) | 1.00 |
| Alcohol intake (g/day) | 1.6 (3.8) | 9.4 (22.8) | 0.68 |
| MRS hepatic fat estimate (%) | 15.5 (6.4) | 15.5 (9.0) | 0.94 |
| Fasting glucose (mg/dl) | 96 (14) | 89 (6) | 0.43 |
| Fasting insulin (IU/ml) | 64.2 (82.8) | 21.0 (11.3) | 0.13 |
| Total cholesterol (mg/dl) | 142 (25) | 151 (23) | 0.61 |
| Triglyceride (mg/dl) | 133 (55) | 165 (80) | 0.72 |
| LDL cholesterol (mg/dl) | 66 (14) | 81 (19) | 0.13 |
| HDL cholesterol (mg/dl) | 48 (11) | 41 (10) | 0.28 |
| Hemoglobin (g/dl) | 14 (1) | 13 (1) | 0.03 |
Values represent mean (standard deviation) unless otherwise indicated.
BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; MRS, magnetic resonance spectroscopy.